Yael L. Maxwell

Experts encourage further exploration of how incorporating biological age using the MFI-5 tool might help with care decisions.

Some question if patients want this information, but others say this tool can put risk into context and prompt lifestyle changes.

EchoPrime was trained on more than 12 million videos; it’s now being tested clinically, with more data expected next year.

The hope is using AI to judge outcomes will ease the high cost and complexity of running big clinical trials, say researchers.

The BMJ cited several issues with the PREVENT-TAHA8 study data, concluding that the “results may not be reliable.”

With such a large reduction, coupled with general skepticism around PUFAs, experts would like to see the trial replicated.

The single-arm INVEST-CTO study showed high procedural success with a two-part intervention, but questions remain.

The real-world Evoque and new TRILUMINATE findings provide an “extension” from the pivotal trials, Dharam Kumbhani says.

More work needs to be done to tease out the mechanisms by which GLP-1 RAs lower the risk of MACE, researchers say.

Given that polygenic risk doesn’t change and only needs to be measured once, researchers advocate greater use.